Yun-Hee Lee

Mrs. Yun-Hee Lee

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
Osung KwonOsung Kwon
Osung Kwon
JMJun-pyo Myong
Jun-pyo Myong
YLYun-Hee Lee
Yun-Hee Lee
YCYeon‐Jik Choi
Yeon‐Jik Choi
JYJeong Eun Yi
Jeong Eun Yi
JLJungmin Lee
Jungmin Lee
Background: Whether the early use of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors have cardioprotective effects following acute myocardial infarction is unknown. Thus, we aimed to evaluate the association between the early initiation of SGLT2 inhibitors and cardiac event rates in patients with diabetes with acute myocardial infarction undergoing percutaneous coronary intervention. Methods and Results: Based on the National Health Insurance claims data in South Korea, patients who received percutaneous coronary intervention for acute myocardial infarction between 2014 and 2018 were analyzed. Patients given SGLT2 inhibitors or other glucose‐lowering drugs were matched based on a propensity score. The primary end point was a composite of all‐cause mortality and hospitalizations for heart failure. Major adverse cardiac events (a composite of all‐cause death, nonfatal myocardial infarction, and ischemic stroke) were compared as the secondary end point. After 1:2 propensity score matching, the SGLT2 inhibitors group (938 patients) and the no use of SGLT2 inhibitors group (1876 patients) were compared. During a median follow‐up of 2.1 years, the early use of SGLT2 inhibitors was associated with lower risks of both the primary end point (9.8% versus 13.9%; adjusted hazard ratio [HR], 0.68 [95% CI, 0.54–0.87]; P =0.002) and secondary end point (9.1% versus 11.6%; adjusted HR, 0.77 [95% CI, 0.60–0.99]; P =0.04). All‐cause mortality and hospitalizations for heart failure were also significantly lower in early users of SGLT2 inhibitors. Conclusions: The early use of SGLT2 inhibitors in patients with diabetes treated with percutaneous coronary intervention for acute myocardial infarction was associated with a significantly lower risk of cardiovascular events, including all‐cause mortality, hospitalizations for heart failure, and major adverse cardiac events.

1 January 2022 in Investigative and Clinical Urology
Verified
Journal Article
Open access
PDF file
JCJin Bong Choi
Jin Bong Choi
KHKyu Hun Han
Kyu Hun Han
YLYun-Hee Lee
Yun-Hee Lee
UHU-Syn Ha
U-Syn Ha
KCKang Jun Cho
Kang Jun Cho
JKJun Sung Koh
Jun Sung Koh
Choi JB, et al. Investig Clin Urol. 2022 Jul;63(4):448-454. https://doi.org/10.4111/icu.20220122

23 June 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JCJin Bong Choi
Jin Bong Choi
JMJun-Pyo Myong
Jun-Pyo Myong
YLYun-Hee Lee
Yun-Hee Lee
IKInah Kim
Inah Kim
JKJung Ho Kim
Jung Ho Kim
UHU-Syn Ha
U-Syn Ha
Background: We examined the association between obesity and prostate cancer based on both body mass index (BMI) and waist circumference (WC) using the National Health Insurance System (NHIS) database for the entire male population of Korea. Methods: A total of 1,917,430 men who underwent at least one health examination in 2009 without a previous diagnosis of any other cancer were tracked through December 2015. The hazard ratio (HR) and 95% confidence interval (CI) value for the association between prostate cancer and obesity were analyzed using multiple Cox regression model. Since there was a statistically significant interaction between WC and BMI, a multiple HR for prostate cancer was estimated with stratifying both WC and BMI to control the interaction between WC and BMI. Results: Without considering WC as an adjustment factor, very weak association between BMI and prostate cancer development risk was observed. When WC was considered as an adjustment factor, no significant change in the HRs for prostate cancer development beyond the reference BMI was observed in the group with WC < 85 cm in the multivariable-adjusted models. However, in the group with WC ≥ 85 cm, the HRs for prostate cancer increased as the BMI increased beyond the reference BMI. In addition, there was a discrepancy in the trend of prostate cancer development according to BMI among the groups with different categories for WC. Conclusion: In groups with abdominal obesity, a significant linear relationship was observed between increasing BMI and prostate cancer risk. Higher the WC category, the stronger was the association with BMI, signifying that the association of BMI with risk of prostate cancer development depends on abdominal obesity.

1 January 2024 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
YLYe-Seo Lee
Ye-Seo Lee
HGHyejin Gu
Hyejin Gu
YLYun-Hee Lee
Yun-Hee Lee
MYMunyoung Yang
Munyoung Yang
HKHyojeong Kim
Hyojeong Kim
Mo-Yeol KangMo-Yeol Kang
Mo-Yeol Kang
Lee YS, et al. J Korean Med Sci. 2024 Oct;39:e316. https://doi.org/10.3346/jkms.2024.39.e316

1 January 2021 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
HKHyung Woo Kim
Hyung Woo Kim
JMJinsoo Min
Jinsoo Min
JCJoon Young Choi
Joon Young Choi
ASAh Young Shin
Ah Young Shin
JMJun-pyo Myong
Jun-pyo Myong
JKJu Sang Kim
Ju Sang Kim
Kim HW, et al. J Korean Med Sci. 2021 Aug;36(36):e246. https://doi.org/10.3346/jkms.2021.36.e246

18 February 2020 in BMJ Open
Verified
Journal Article
Open access
PDF file
JMJinsoo Min
Jinsoo Min
HKHyung Woo Kim
Hyung Woo Kim
HSHelen R Stagg
Helen R Stagg
MLMarc Lipman
Marc Lipman
MRMolebogeng X Rangaka
Molebogeng X Rangaka
JKJu Sang Kim
Ju Sang Kim
Introduction South Korea regards tuberculosis (TB) incidence in congregate settings as a serious problem. To this end, systematic latent TB infection (LTBI) diagnosis and treatment were provided to approximately 1.2 million individuals in high-risk congregate settings. Methods and analysis We designed a prospective cohort study of individuals tested for LTBI, based on the data collected on all persons screened for LTBI as part of the 2017 congregate settings programme in South Korea. Four types of databases are kept: LTBI screening database (personal information and LTBI test results), national health information (NHI) database (socio-demographic data and comorbidities), public healthcare information system (PHIS) database, and the Korean national TB surveillance system database (TB outcomes). Information regarding LTBI treatment at private hospitals and public health centres is collected from NHI and PHIS databases, respectively. The screening data are cleaned, duplicates are removed, and, where appropriate, re-coded to analyse specific exposures and outcomes. The primary objective is to compare the number of active TB cases prevented within 2 years between participants undergoing treatment and not undergoing treatment in the LTBI screening programme in congregate settings. Cascade of care for LTBI diagnosis and treatment will be evaluated among those with a positive LTBI test result. A Cox proportional hazards model will be applied to determine the risk factors for developing active TB. Ethics and dissemination The protocol is approved by the institutional review boards of Incheon St. Mary’s Hospital, the Catholic University of Korea. Study results will be disseminated through peer-reviewed journals and conference presentations. Trial registration number KCT0003905